Nimotuzumab in Combination With Concurrent Radiotherapy and Cisplatin Is Active in Locally Advanced SCCHN

(July 19, 2018)

Nimotuzumab in combination with concurrent radiotherapy and cisplatin provides significant clinical benefits in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). About Head and Neck Cancer Head and neck cancers include... Continue Reading


FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer

(July 17, 2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC... Continue Reading


Cyramza Improves Survival in Poor-Prognosis Liver Cancer

(July 12, 2018)

Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab) significantly improves survival in a subset... Continue Reading


Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

(July 10, 2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless... Continue Reading


Aromasin plus Ovarian Suppression Yields Benefit in High-risk Premenopausal Breast Cancer Patients

(July 9, 2018)

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence... Continue Reading


Engineering the Common Cold Virus Appears to be Promising Treatment Approach for Some Brain Tumors

(July 6, 2018)

A “smart bomb” oncolytic adenovirus appears to induce dramatic responses with long-term survival in recurrent high-grade gliomas, according to the early results of a study published in The Journal of Clinical Oncology. Glioblastoma is the... Continue Reading


Xalkori® Receives FDA Breakthrough Therapy Designation for Anaplastic Large Cell Lymphoma

(July 3, 2018)

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori® (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase... Continue Reading


FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion,

(June 25, 2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval... Continue Reading


Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer

(June 25, 2018)

The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP... Continue Reading


Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer

(June 22, 2018)

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda... Continue Reading


U.S. FDA Agrees to Review Talazoparib for Advanced and Triple Negative Breast Cancer for Treatment of Patients with an Inherited BRCA Mutation

(June 21, 2018)

The U.S. Food and Drug Administration accepted for filing and granted Priority Review designation for Pfizer’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which compared talazoparib to chemotherapy... Continue Reading


mFOLFIRINOX Found Superior to Gemzar for Treatment Surgically Resected Pancreatic Cancer

(June 19, 2018)

The results of a recently presented clinical study at the American Society of Clinical Oncology meetings last week suggest that more aggressive chemotherapy treatment improves outcomes compared to single agent Gemzar (gemcitabine) chemotherapy which has... Continue Reading


« Previous PageNext Page »